Axonics ModulationTechnologies Inc

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axonics reports record Q4 revenue, eyes global expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q4 2022, with record revenue, solid margins, and profitability, while reiterating revenue guidance for 2023.
The company's focus on innovation, market leadership in sacral neuromodulation, and global expansion plans position it well for future growth despite challenges in international markets and legal uncertainties.
Opportunities in the U.S. and Asian markets, coupled with strategic initiatives like direct-to-consumer campaigns and product enhancements, offer avenues for sustained revenue growth and market dominance.

Axonics reports robust Q1 earnings, eyes market expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q1 2023, driven by revenue growth, operational efficiency, and strategic guidance updates for FY 2023.
The company's strengths lie in its robust commercial team, successful marketing campaigns, focus on innovation, and leadership's commitment to disciplined growth strategies.
While facing challenges such as legal uncertainties, coverage limitations, and margin management, Axonics has opportunities for market expansion, acquisitions, and technology advancements.
Overall, Axonics' performance, strengths, challenges, and opportunities position the company for continued growth and market leadership in the neuromodulation industry.

Axonics Modulation Technologies Reports Record Q2 Revenue Growth

Axonics Modulation Technologies delivered a strong performance in Q2, driven by revenue growth and operational efficiency.
The company's strengths lie in international expansion, robust commercial efforts, and continuous product innovation.
Challenges include legal uncertainties, market dynamics, and strategic positioning in a competitive landscape.
Opportunities for growth include market expansion, rising adoption trends, and enhancing customer experience.

Axonics reports robust Q3 earnings, eyes growth through innovation

Axonics delivered strong financial performance, driven by SNM and Bulkamid revenue growth and improved margins.
The company's focus on innovation, customer feedback, and market leadership positions it well for future growth.
Challenges include maintaining growth momentum, high rep productivity, and balancing marketing strategies.
Opportunities lie in expanding product offerings, market share, and leveraging direct-to-consumer campaigns for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-57

Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022. Axonics is scheduled to present at 12:00 p.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website. About Axonics Base

Axonics® to Participate in SVB Leerink Virtual Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence (UI) prevalence in the U.S. The study, titled “Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data,” was published in the peer-reviewed jour

New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence

Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2021. 4Q21 total company net revenue is expected to be in the range of $52.9 to $53.3 million, an increase of 53% compared to $34.8 million in the prior year period. 4Q21 sacral neuromodula

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Raymond W. Cohen, chief executive officer of Axonics, has been awarded the 2021 Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council (SoCalBio). “This award recognizes bioscience and healthcare entrepreneurs and change-makers in the grea

Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 1 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Companies were ranked based on the percentage growth in th

Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™

SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Deloitte today released its "North America Technology Fast 500," an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences, fintech, and energy tech sectors, now in its 27th year. Axonics, Inc. claimed the top spot with a growth rate of 87,037% from 2017 to 2020.

Deloitte Unveils 2021 North America Technology Fast 500 Rankings

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2021. In advance of the virtual conference, a pre-recorded fireside chat with Axonics senior management will be made available on Monday, November 22 at 10:00 AM Eastern Time. Interested parties may a

Axonics® to Participate in Piper Sandler Virtual Healthcare Conference

Axonics, Inc. (AXNX) CEO Raymond Cohen on Q3 2021 Results - Earnings Call Transcript

Axonics (AXNX) delivered earnings and revenue surprises of 17.39% and -3.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the third quarter ended September 30, 2021. “We are pleased with this quarter's revenue result considering the significant impact the surge in Covid-19 Delta variant cases had on elective procedure volumes in August and September, in addition to staffing sh

Axonics® Reports Third Quarter 2021 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has been named by the Orange County Business Journal as the fastest growing publicly traded company in Orange County. Companies were ranked based on the growth in their revenue over a two-year period. Axonics reported $150.3 million of revenue in the trailing twelve months ended June 30, 2021,

Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-2

Axonics® to Report Third Quarter 2021 Financial Results on November 4

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) t

Axonics® Provides Additional Update on Inter Partes Review Proceedings

Medtronic

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral neuromodulation device family, the InterStim™ systems.

U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Patents

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three of the six Medtronic patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) t

Axonics® Announces Partial Decision on Inter Partes Review Proceedings

Axonics' stock price just hit its 52-week high, but its momentum means it's unlikely to last.

Axonics: Buy at the High?

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management will present at the following virtual investor conferences: Event: Wells Fargo Healthcare Conference Date: Thursday, September 9, 2021 Time: 12:00 p.m. Eastern Time Event: Morgan Stanley Healthcare Conference Date: Monday, September 13, 2021 Time: 12:30 p

Axonics® to Participate in Upcoming Investor Conferences

Axonics, Inc.'s (AXNX) CEO Raymond Cohen on Q2 2021 Results - Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021. “This quarter's record revenue result reflects the growing demand for our best-in-class incontinence solutions,” said Raymond W. Cohen, chief executive officer of Axonics. “Clinical outcomes and satisfaction with our

Axonics® Reports Second Quarter 2021 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the appointment of Esteban López, M.D., MBA, to its board of directors, effective immediately. “Axonics is fortunate to have someone of Dr. López's character and extensive experience join our board of directors,” said Raymond W. Cohen, CEO of Axonics. “Given his thought leaders

Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-21

Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS). Axonics has designed its new non-rechargeable SNM system to replicate key features of its currently marketed, FDA-a

Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans. The FDA previously approved 1.5T and 3.0T MRI conditional labeling for using head and full-body transmit coils for the implantable components of the Axonics r-SNM® system.

News for Axonics ModulationTechnologies Inc Stock (AXNX)